Is Sermorelin Legal in Louisiana? How to Access It With a Prescription

The Short Answer on Sermorelin's Legal Status in Louisiana

Sermorelin is legal in Louisiana with a valid prescription from a licensed practitioner. No Louisiana state statute independently bans it, and it carries no DEA controlled-substance classification. The legal complexity comes from the federal compounding layer: the FDA does not recognize sermorelin as an FDA-approved finished drug product, so every vial dispensed in the United States is compounded, and that compounding must comply with federal 503A or 503B standards as well as Louisiana Board of Pharmacy rules.

Patients who obtain sermorelin without a prescription, from overseas sources, or from research-chemical vendors operate outside the law. The distinction matters clinically and legally.

What Sermorelin Actually Is

Sermorelin acetate is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile secretion of growth hormone (GH). Because GH secretion remains under normal physiologic feedback, sermorelin carries a lower risk of GH excess than exogenous recombinant GH (rhGH). FDA-approved rhGH products such as somatropin are listed under 21 CFR Part 216 as finished drugs; sermorelin is not on that list in its compounded injectable form.

Sermorelin was briefly FDA-approved as Geref Diagnostic (sermorelin acetate for injection, 1 mcg/kg IV) for pediatric GH-deficiency diagnosis, but that product was withdrawn from the commercial market in 2008 for business reasons, not safety concerns. The FDA's drug-shortage and discontinuation records confirm no currently approved sermorelin finished-drug product exists in the United States.

Why the Compounding Gray Zone Exists

Because no FDA-approved finished sermorelin product is on the market, every unit dispensed today is produced by a compounding pharmacy operating under:

• Section 503A of the Federal Food, Drug, and Cosmetic Act (patient-specific prescriptions, traditional compounding pharmacies)
• Section 503B of the FDCA (outsourcing facilities, larger-batch compounding for office use)

The FDA periodically updates its "bulk drug substances" lists under 503A and 503B. Sermorelin has not been placed on the FDA's Category 1 (nominated, under review) or Category 2 (not appropriate for compounding) bulk-substances lists as of the most recent published update. The FDA's current 503A bulk-drug substance list is publicly searchable. This absence from the "do-not-compound" list means sermorelin can currently be compounded legally under 503A and 503B, provided the pharmacy meets all other requirements.

Federal Regulatory Framework: FDA, DEA, and Compounding Law

Understanding how federal law treats sermorelin is the first step before examining what Louisiana adds on top of it.

DEA Scheduling

Sermorelin is not listed in Schedule I through V of the Controlled Substances Act. The DEA's list of controlled substances, published at 21 USC 812 and updated in the DEA Diversion Control Division database, does not include sermorelin or GHRH analogs as a class. This means no DEA registration is required specifically to prescribe sermorelin, though any prescriber must obviously hold a valid DEA number for controlled substances they also prescribe.

FDA Finished-Drug vs. Compounded-Drug Distinction

The FDA draws a hard line between an approved finished drug (manufactured under cGMP, assigned an NDA or ANDA) and a compounded drug. Sermorelin falls in the compounded category. Under 21 USC 353b, 503B outsourcing facilities must register with the FDA, pay annual fees, and submit adverse-event reports. 503A traditional pharmacies are subject to state board oversight primarily but must still not compound a drug that is essentially a copy of an FDA-approved product. Because no approved sermorelin product currently exists commercially, the "essentially a copy" bar is not triggered.

The 2023 FDA Peptide Guidance and Its Impact

In 2023 the FDA proposed new guidance that would restrict certain peptides from 503A compounding. The FDA's draft guidance document on bulk drug substances under 503A identified several peptides for review. Sermorelin was not placed on the final restricted list at the time of this writing. Prescribers and patients should monitor FDA compounding news releases because the regulatory picture can shift within a single calendar year.

Louisiana State Law: Pharmacy Board Rules and the Medical Practice Act

Louisiana does not have a separate statute that specifically addresses peptide therapy or sermorelin. Legal access is governed by three overlapping state frameworks.

Louisiana Board of Pharmacy Compounding Rules

The Louisiana Board of Pharmacy (LBPharm) requires that all sterile compounding pharmacies operating in or shipping into Louisiana hold an appropriate state permit. Louisiana RS 37:1161 through 37:1177 govern pharmacy licensure broadly; sterile compounding specifically requires compliance with USP General Chapter 797, which covers environmental monitoring, beyond-use dating, and microbial testing for injectable preparations such as sermorelin. A pharmacy that does not meet USP 797 standards is violating Louisiana law regardless of federal status.

Louisiana also accepts out-of-state compounders that are licensed in their home state and registered as non-resident pharmacies with LBPharm. Many telehealth-linked 503A pharmacies operate across state lines legally under this framework.

The Louisiana Medical Practice Act

Under Louisiana RS 37:1261 et seq., licensed MDs and DOs may prescribe any non-controlled substance that is within their scope of practice. The Louisiana State Board of Medical Examiners (LSBME) has not issued a specific prohibition on prescribing sermorelin. Nurse practitioners with full prescriptive authority (Louisiana RS 37:913) and physician assistants with a supervising physician may also prescribe it. Prescribers remain responsible for establishing a valid patient-provider relationship, conducting a proper clinical evaluation, and documenting a legitimate medical indication before writing a sermorelin prescription.

Telehealth Prescribing in Louisiana

Louisiana expanded telehealth prescribing access under Louisiana RS 40:978.1 and related statutes updated post-2020. A Louisiana-licensed prescriber may evaluate a patient via synchronous audio-video telemedicine and then transmit a sermorelin prescription to a Louisiana-registered compounding pharmacy. The Centers for Medicare and Medicaid Services telehealth guidance and the Louisiana Telehealth Commission confirm that prescribing via telehealth for non-controlled substances requires only a standard clinical evaluation, not an in-person visit. This makes telehealth a fully legal path to sermorelin access for Louisiana residents.

Clinical Indications and Patient Selection

Sermorelin is prescribed most often for adult GH deficiency, age-related GH decline, and body-composition goals in otherwise healthy adults. No FDA-approved indication currently exists in its compounded form, making every clinical use off-label. Off-label prescribing is legal and common; the American Association of Clinical Endocrinology (AACE) growth hormone guidelines define adult GH deficiency criteria that many prescribers use as a clinical anchor.

IGF-1 as the Monitoring Marker

Growth hormone itself has a very short half-life (minutes) and pulses episodically, making direct GH measurement unreliable for outpatient monitoring. Insulin-like growth factor-1 (IGF-1), produced hepatically in response to cumulative GH signaling, is the standard surrogate. A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirms IGF-1 as the primary biochemical endpoint for GH-axis therapy monitoring. Most protocols obtain a baseline IGF-1, recheck at 6 weeks, and adjust dose if IGF-1 remains below the age-adjusted reference range.

Who Is a Candidate?

Adults with biochemically confirmed low IGF-1, symptoms of GH insufficiency (poor sleep quality, reduced lean mass, increased visceral adiposity, fatigue), and no history of active malignancy or pituitary tumor are the clearest candidates. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults sets a stimulated GH threshold of <3 mcg/L (by glucagon stimulation test or insulin tolerance test) for confirmed deficiency. Sermorelin is not a replacement for stimulation testing in patients with suspected organic hypopituitarism; it is most appropriate for functional or age-related GH decline.

Contraindications to Know

Active malignancy is an absolute contraindication because GH and IGF-1 can promote tumor growth. A 2021 meta-analysis in JAMA Oncology examined IGF-1 axis dysregulation and cancer risk, reinforcing caution in patients with personal or strong family histories of hormone-sensitive cancers. Pregnancy and uncontrolled hypothyroidism are relative contraindications; thyroid status should be optimized before starting sermorelin because GH secretion is blunted in hypothyroid states. The American Thyroid Association guidelines recommend TSH normalization before evaluating the GH axis.

Typical Sermorelin Protocol Used in Louisiana Clinics

Starting Dose and Administration

Most Louisiana prescribers following established compounding-pharmacy protocols start sermorelin at 200 to 300 mcg subcutaneously administered at bedtime. The bedtime timing is deliberate: endogenous GH release peaks during slow-wave sleep, and sermorelin amplifies that pulse. Dose is typically titrated to 500 mcg if IGF-1 response is inadequate at 6 weeks.

The reconstituted solution is drawn into a small insulin syringe (0.3 to 0.5 mL) and injected into the abdomen or thigh subcutaneous tissue. Rotation of injection sites reduces lipodystrophy risk. The FDA's guidance on subcutaneous drug administration and USP 797 standards both inform how compounding pharmacies prepare the lyophilized powder and set beyond-use dates (typically 30 days refrigerated after reconstitution).

Duration and Cycling

A standard initial course is 3 to 6 months of nightly dosing. Some protocols use a 5-days-on, 2-days-off schedule to theoretically prevent receptor downregulation, though published evidence in the journal Endocrinology on optimal cycling schedules for GHRH analogs in adults is limited. After 3 to 6 months, providers reassess IGF-1, symptoms, and body-composition metrics before deciding to continue, pause, or add an adjunct peptide.

Combination With GHRP Agents

Some practitioners combine sermorelin with a growth hormone-releasing peptide (GHRP) such as ipamorelin to achieve synergistic GH release through two independent receptor pathways. A 2019 review in Frontiers in Endocrinology describes the dual-receptor mechanism: GHRH analogs act on GHRH-R while GHRPs act on ghrelin receptor (GHS-R1a). This combination may produce larger GH pulses than either agent alone. Both compounds require compounding pharmacy sourcing and separate prescriptions in Louisiana.

How to Access Sermorelin Legally in Louisiana: Step-by-Step

Getting sermorelin legally in Louisiana follows a clear sequence. Each step has a corresponding legal or clinical anchor.

Step 1: Find a Qualified Prescriber

A Louisiana-licensed MD, DO, NP (with prescriptive authority), or supervising PA can prescribe sermorelin. Endocrinologists, anti-aging medicine specialists, and functional medicine physicians are the most common prescribers. Many operate via telehealth, allowing patients anywhere in Louisiana to schedule an evaluation without traveling to New Orleans or Baton Rouge. The LSBME physician directory allows verification of any physician's license status before booking.

Step 2: Complete a Clinical Evaluation

The evaluation must include a thorough history, review of symptoms, and baseline labs. At minimum, labs should include:

• IGF-1 (age-adjusted reference range)
• Comprehensive metabolic panel
• Fasting lipid panel
• TSH and free T4
• Complete blood count
• In men, total and free testosterone; in women, estradiol and FSH if perimenopausal

The Endocrine Society's testing recommendations for GH-axis evaluation provide a clinical evidence base for this panel. Without documented baseline labs, a sermorelin prescription lacks clinical justification and could expose the prescriber to board scrutiny.

Step 3: Receive a Written Prescription

The prescriber issues a patient-specific prescription naming the patient, the compound (sermorelin acetate), concentration, volume, route, frequency, and quantity. This prescription must be transmitted to a compounding pharmacy, not a retail chain, because no finished sermorelin product is commercially available. FDA 503A rules under 21 USC 353a require the prescription to be patient-specific for 503A pharmacies; 503B outsourcing facilities may supply prescribers directly for office use.

Step 4: Use a Louisiana-Registered Compounding Pharmacy

The dispensing pharmacy must hold an active Louisiana non-resident pharmacy permit or be a Louisiana-based sterile compounder registered with LBPharm. The National Association of Boards of Pharmacy (NABP) database lists pharmacies that meet multistate accreditation standards (e.g., PCAB accreditation). Using a PCAB-accredited pharmacy reduces the risk of receiving substandard product. Patients should ask their prescriber which pharmacy they work with and verify that pharmacy's accreditation status directly.

Step 5: Follow Monitoring and Safety Protocols

After the first 6 weeks of therapy, an IGF-1 recheck is the minimum standard. A 2022 paper in Growth Hormone and IGF Research found that IGF-1 response to GHRH analog therapy varies significantly by baseline age, sex, and body-mass index, with men over 50 showing a mean IGF-1 increase of approximately 45 ng/mL over 12 weeks at 300 mcg/night. Providers should target IGF-1 in the upper half of the age-adjusted normal range, not above it. Supraphysiologic IGF-1 raises concern for acromegaly-like effects over long treatment courses.

Risks of Obtaining Sermorelin Outside Legal Channels

Patients who bypass the prescription pathway face concrete dangers beyond legal exposure.

Product Quality and Contamination

Sermorelin purchased from online research-chemical vendors or overseas pharmacies is not manufactured under USP 797 or cGMP standards. An FDA warning letter database search reveals multiple actions against compounders that failed sterility and potency testing. Injectable contaminated peptides carry risks of bacterial endotoxin reactions, particulate emboli, and misdosed peptide content.

Legal Exposure

Importing an unapproved drug without an FDA personal importation exemption violates 21 USC 331. The FDA's import alert system (Import Alert 66-41) covers unapproved new drugs including peptides not cleared for importation. Louisiana law mirrors federal prohibition on dispensing prescription drugs without a valid prescription under RS 40:972.

No Medical Oversight

Without a prescribing clinician, patients have no mechanism to monitor IGF-1, adjust dosing, or catch early signs of adverse effects. Fluid retention, carpal tunnel-like symptoms, and injection-site reactions are known class effects of GH secretagogues. A review in the European Journal of Endocrinology found that GH-axis therapy without monitored endpoints produced suboptimal outcomes and higher rates of side effects compared with protocol-guided care.

What Louisiana Patients Should Ask Their Provider

Before starting sermorelin therapy, patients should ask specific questions to confirm they are receiving legitimate care:

• Which pharmacy will fill my prescription, and is it PCAB-accredited?
• What IGF-1 level are you targeting for me specifically?
• How will we know if my dose needs to change at 6 weeks?
• Are you prescribing sermorelin alone or in combination with another peptide?
• What is the plan if my IGF-1 goes above the normal range?
• How does sermorelin fit into my overall hormone optimization plan?

The Endocrine Society's position statement on off-label hormone use emphasizes shared decision-making and documented clinical rationale as the standard for any off-label prescription. These questions help patients hold providers accountable to that standard.

Frequently Asked Questions